Research Progress on Antitumor Mechanism of Apatinib
10.3971/j.issn.1000-8578.2021.20.0302
- VernacularTitle:阿帕替尼抗肿瘤作用机制研究进展
- Author:
Lingying ZHAO
1
;
Wenqing ZHANG
;
Cunxi LI
;
Tianhui HU
Author Information
1. Cancer Research Center, School of Medicine, Xiamen University, Xiamen 361102, China
- Publication Type:Research Article
- Keywords:
Apatinib;
Antiangiogenic drugs;
Tumor
- From:
Cancer Research on Prevention and Treatment
2021;48(1):7-11
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, antiangiogenic drugs based on VEGF and VEGFRs signaling pathway have been widely used in the treatment of malignant tumors. Apatinib is an orally bioavailable small-molecule antiangiogenic agent and can specifically inhibit the tyrosine kinase activity of VEGFR, thereby inhibiting tumor angiogenesis. Apatinib is the first-level recommendation of third-line treatment of gastric cancer in CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer published in 2018. Apatinib has been proved to be effective and safe in gastric, lung and breast cancers. In addition, the drug shows great potential in the treatment of a variety of solid tumors. This article reviews the recent progress on the mechanism, clinical efficacy, related efficacy predictors of apatinib and its combination with other antitumor drugs.
